Business Wire

BACARDI

25.3.2020 18:38:07 CET | Business Wire | Press release

Share
From USA to France and From UK to Mexico, Bacardi Diverts Global Production to Increase Hand Sanitizer Supply for Local Communities

Family-owned Bacardi has expanded its commitment across countries and brands to help produce more than 267,000 gallons (1.1 million liters) of hand sanitizers, as worldwide demand continues to exceed supply in efforts to reduce the risk of COVID-19. This week, eight Bacardi-owned manufacturing sites across the United States, Mexico, France, England, Italy and Scotland are joining the efforts, following last week’s announcement that Bacardi in Puerto Rico would supply alcohol to make hand sanitizers. Across the sites, Bacardi is diverting its global production power, resources and processes to supply the much-needed alcohol essential for the increased production of hand sanitizers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200325005615/en/

Bacardi is also playing a part in donating these products to local organizations and emergency responders, as well as its employees and contractors. In addition, the company is providing alcohol at cost to select partner companies looking to ramp up their production of hand sanitizers for commercial sale. These temporary, emergency actions at all locations will not disrupt the supply of brands in the Bacardi portfolio.

“Over our 158-year history, we have risen to many challenges and we are doing the same again in response to COVID-19,” said Jean-Marc Lambert, SVP Global Operations for Bacardi. “All our brands and partners involved in this initiative will help people most in need benefit from the supply of these hand sanitizers. Our goal is to make a very real difference in the fight against COVID-19.”

The current list of sites providing support either immediately or in the coming week are:

  • BACARDÍ rum in Puerto Rico – partnered with Puerto Rico based manufacturer Olein Refinery to provide raw materials that will enable the production of more than 1.7M units of 10-ounce (300 ml) hand sanitizers. Donated product to local USPS, firefighters, police and non-profit Somos Unidos (United Way);
  • Bacardi Bottling Corporation in Jacksonville, FL, USA – is planning to help produce approximately 23,000 gallons (87,000 liters) to make 120,000 units of 25-ounce (750 ml) bottles hand sanitizer for donation to local hospitals, firefighters and police. In addition, the team will supply 7,600 gallons (29,000 liters) to nearby manufacturers.
  • BACARDÍ rum in Tultitlán, Mexico – supplying more than 5,200 gallons (20,000 liters) of alcohol to nearby manufacturer, Grupo Sterk, to help increase production of hand sanitizer by approximately 6,300 gallons (24,000 liters), of which 2,100 gallons (8,000 liters) will be donated by Bacardi to local communities in Tultitlán, Arandas and Atotonilco;
  • GREY GOOSE® vodka in Cognac, France – will supply 7,600 gallons (29,000 liters) of alcohol per day to French companies to increase supply of hand sanitizers by 9,500 gallons (36,000 liters) for local pharmacies, hospitals and the emergency services;
  • BOMBAY SAPPHIRE® gin in Hampshire, England – is helping to produce a small quantity of hand sanitizers that will be donated to local doctors, chemists and care homes;
  • MARTINI in Pessione, Italy – is supplying alcohol for the production of 1,000 7-ounce (200ml) hand sanitizers for the local community, Red Cross and local emergency services;
  • DEWAR’S® Blended Scotch Whisky in Aberfeldy, Scotland – is helping to produce a small quantity of hand sanitizers for the Scottish Ambulance Association among other local community groups;
  • ANGEL’S ENVY® Kentucky Straight Bourbon in Louisville, KY, USA – is supplying nearly 1,000 gallons (3,800 liters) of alcohol to create approximately 16,000 8-ounce (250 ml) bottles of free hand sanitizers for first responders and healthcare professionals.

All hand sanitizers produced in collaboration with Bacardi contain more than the minimum alcohol content recommended by the World Health Organization for containing the spread of the virus.

About Bacardi

The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded more than 158 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 7,000, operates production facilities in 11 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit www.bacardilimited.com or follow us on Twitter , LinkedIn or Instagram .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release

The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye